ReviewCancer letters2022
Precision intervention for prostate cancer: Re-evaluating who is at risk.
Review in Cancer letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Identification of druggable genetic targets for prostate cancer risk based on mendelian randomization and single-cell RNA sequencing.International urology and nephrology · 2025Article
- Integrating multi-cohort machine learning and clinical sample validation to explore peripheral blood mRNA diagnostic biomarkers for prostate cancer.Cancer cell international · 2025Article
- Comparing and Combining Artificial Intelligence and Spectral/Statistical Approaches for Elevating Prostate Cancer Assessment in a Biparametric MRI: A Pilot Study.Diagnostics (Basel, Switzerland) · 2025Article
- Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer.Molecular cancer · 2025Article
- Machine learning models for predicting prostate cancer recurrence and identifying potential molecular biomarkers.Frontiers in oncology · 2025Article
- Precision prevention in occupational health: a conceptual analysis and development of a unified understanding and an integrative framework.Frontiers in public health · 2024Article
- Single-port and multiport robot-assisted radical prostatectomy: A meta-analysis.Prostate international · 2023Review
- The Transcriptomic Profiles ofInternational journal of molecular sciences · 2023Article
- Article
- An anoikis-related gene signature for prediction of the prognosis in prostate cancer.Frontiers in oncology · 2023Article
- Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes.BMC medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored by active surveillance rather than undergoing immediate treatment. However, a subset of men will progress to advanced prostate cancer which may result in lethality, and these men are likely to benefit from early intervention to prevent or delay such progression. For this high-risk group, which includes aged men, men of African descent, and those with a hereditary predisposition to prostate cancer, informed risk stratification can be the cornerstone of clinical decision making and treatment intervention. In this review, we discuss the importance of a precision intervention approach that considers the cumulative risk for a given patient or population to develop prostate cancer or to progress to lethal disease, with particular focus on the interplay of major determinants of high-risk disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.